IRAK4 and Alzheimer disease: To further elucidate the role of the IRAK4/NF-κB axis in AD, we combined the IRAK4 inhibitor Zimlovisertib and the NF-κB inhibitor QNZ to treat DNFB-induced AD mice by either transdermal drug delivery systems (TDDs) or oral administration (p.o.).